Zhang Lijun, Rao Yao, Li Zhongyan, Fan Mei, Xiang Zongjun, Wang Jingsong
Department of Clinical Pharmacy, Dazhou Central Hospital, Dazhou, Sichuan, People's Republic of China.
Department of Respiratory, Dazhou Central Hospital, Dazhou, Sichuan, People's Republic of China.
Infect Drug Resist. 2025 Jun 25;18:3103-3115. doi: 10.2147/IDR.S524214. eCollection 2025.
lung disease has gradually become a common clinical condition, with its incidence rate continuously rising, especially among patients with weakened immune function or those with chronic lung diseases. Given the high resistance of to antibiotics, the options for antibiotics are very limited. Additionally, long treatment times and poor patient compliance lead to low cure rates and high recurrence rates, making it one of the significant public health challenges threatening global health. This article presents two cases of patients diagnosed with lung disease using next-generation metagenomic sequencing technology. It reviews and analyzes the current research on along with details from these cases. Furthermore, this article emphasizes the necessity of timely, regular, and comprehensive treatment for lung disease. Meanwhile, we call for the formulation of robust prevention strategies, the optimization and innovation of treatment regimens, and the enhancement of follow-up management after cure to improve the understanding and handling capabilities of lung disease, thereby addressing the increasing clinical challenges.
肺部疾病已逐渐成为一种常见的临床病症，其发病率持续上升，尤其是在免疫功能低下的患者或患有慢性肺部疾病的人群中。鉴于[病原体名称]对抗生素具有高度耐药性，抗生素的选择非常有限。此外，治疗时间长且患者依从性差导致治愈率低、复发率高，使其成为威胁全球健康的重大公共卫生挑战之一。本文介绍了两例使用下一代宏基因组测序技术诊断为[疾病名称]肺部疾病的患者案例。回顾并分析了当前关于[疾病名称]的研究以及这些案例的详细情况。此外，本文强调了对[疾病名称]肺部疾病进行及时、规范和综合治疗的必要性。同时，我们呼吁制定强有力的预防策略，优化和创新治疗方案，并加强治愈后的随访管理，以提高对[疾病名称]肺部疾病的认识和处理能力，从而应对日益增加的临床挑战。
需注意，原文中部分关键信息缺失（如具体的病原体名称、疾病名称等），我按照格式要求进行了翻译，但实际翻译时应根据准确信息进行调整。
